Under-reporting of adverse effects of tesofensine. — VialBase Research

Summary

This is a piece of correspondence in The Lancet, indexed by PubMed as a Letter and a Comment, published in 2013 under the title “Under-reporting of adverse effects of tesofensine.” Its listed authors are Astrup A, Madsbad S, Breum L, et al. — the same lead author who headed the pooled analysis of tesofensine’s weight-loss effect in Parkinson’s and Alzheimer’s disease trials (PMID 18356831). The PubMed record contains no abstract, so the content of the letter, the specific adverse effects at issue, and the direction of the argument — whether the authors are alleging under-reporting or responding to such an allegation — cannot be established from the indexed metadata and must be read in the published correspondence itself. What the record does establish, and what belongs in any honest account of the compound, is that the adequacy of adverse-event reporting in the tesofensine obesity programme became a subject of formal published dispute in the world’s most prominent general medical journal. It appeared in the same journal and the same year as The Lancet’s Expression of Concern about the pivotal randomised, double-blind, placebo-controlled tesofensine obesity trial (PMID 23561987). Taken together, the two items mean that both the efficacy claim and the safety record of tesofensine’s central trial were subject to public scrutiny in 2013.

Key Findings

• The Lancet published correspondence titled “Under-reporting of adverse effects of tesofensine” in 2013 (Lancet 2013;382(9887):127)
• PubMed publication types are Letter and Comment: this is correspondence attached to another publication, not original research
• Listed authors are Astrup A, Madsbad S, Breum L, et al.; Astrup is also lead author of the pooled tesofensine weight-loss analysis (PMID 18356831)
• No abstract is indexed, so the substance and direction of the exchange must be read in the letter itself rather than inferred
• It was published in the same journal and calendar year as the Expression of Concern about the pivotal tesofensine obesity trial (PMID 23561987)

Relevance to Tesofensine

The safety story for Tesofensine is not settled, and this record is the reason to say so plainly. Beyond the measurable dose-dependent heart rate increase documented in the pooled neurology-trial analysis, the completeness of adverse-event reporting in the tesofensine obesity programme was itself contested in The Lancet in 2013. That contest sits alongside the journal’s Expression of Concern about the pivotal obesity trial from the same year, and the combination is decisive for how this compound should be described: tesofensine’s headline weight-loss claim rests on a trial subject to a published Expression of Concern, and the adverse-effect profile attached to that programme has been publicly disputed in the same journal. A vendor page that quotes the weight-loss percentage while omitting both facts is not describing the evidence base accurately. Because no abstract is indexed for this letter, the note deliberately stops short of characterising who argued what — the existence and location of the dispute is the citable fact.

Citation

Astrup A, Madsbad S, Breum L, et al. Under-reporting of adverse effects of tesofensine. Lancet (London, England). 2013;382(9887):127. doi:10.1016/S0140-6736(13)61563-9.

See Also

• Parent compound: Tesofensine